表紙
市場調査レポート

難治性多発性骨髄腫 - パイプライン分析

Refractory Multiple Myeloma - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 247792
出版日 ページ情報 英文 463 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
難治性多発性骨髄腫 - パイプライン分析 Refractory Multiple Myeloma - Pipeline Review, H2 2015
出版日: 2015年09月30日 ページ情報: 英文 463 Pages
概要

難治性多発性骨髄腫は、一次療法あるいはサルベージ療法の時に無反応であるか、最後の治療の60日間以内に進行する疾患であると定義されています。 症候は、出血、神経障害、皮膚障害、骨の圧痛または疼痛、感染症、病的骨折と脊髄圧縮などです。

当レポートでは、静脈性足潰瘍(下腿潰瘍)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

難治性多発性骨髄腫 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • 協和発酵キリン
  • Sanofi
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Piramal Enterprises Limited
  • Prolexys Pharmaceuticals, Inc.
  • ZIOPHARM Oncology, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • アステラス製薬
  • Pfizer Inc.
  • Sigma-Tau S.p.A.
  • Astex Pharmaceuticals, Inc.
  • Exelixis, Inc.
  • Celgene Corporation
  • Onyx Pharmaceuticals, Inc.
  • Incyte Corporation
  • Immunomedics, Inc.
  • Oncolytics Biotech Inc.
  • Patrys Limited
  • Curis, Inc.
  • Pharmacyclics, Inc.
  • Array BioPharma Inc.
  • MorphoSys AG
  • Senesco Technologies, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Synta Pharmaceuticals Corp.
  • Dicerna Pharmaceuticals, Inc.
  • Acceleron Pharma, Inc.
  • Altor BioScience Corporation
  • Arno Therapeutics, Inc.
  • Stemline Therapeutics, Inc.
  • Onconova Therapeutics, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Pharma Mar, S.A.
  • CureTech Ltd.
  • AbbVie Inc.
  • Oncopeptides AB
  • Senhwa Biosciences, Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ixazomib citrate
  • daratumumab
  • ibrutinib
  • carfilzomib
  • elotuzumab
  • plitidepsin
  • bendamustine hydrochloride
  • AT-9283
  • AT-7519
  • PAT-SM6
  • ruxolitinib phosphate
  • filanesib
  • darinaparsin
  • ALT-801
  • pidilizumab
  • PM-00104
  • pomalidomide
  • trametinib dimethyl sulfoxide + uprosertib
  • DKN-01
  • Melflufen
  • Circularly Permuted TRAIL
  • alisertib
  • linsitinib
  • milatuzumab
  • AR-42
  • PRLX-93936
  • oprozomib
  • cabozantinib s-malate
  • SNS-01T
  • ganetespib
  • SL-401
  • TH-302
  • P-276
  • MOR-202
  • KW-2478
  • palbociclib
  • marizomib
  • luminespib
  • plerixafor
  • ricolinostat
  • LGH-447
  • selinexor
  • tabalumab
  • daratumumab
  • BMS-833923
  • dalantercept
  • SAR-650984
  • dasatinib
  • pelareorep
  • rigosertib sodium
  • MLN-0128
  • ulocuplumab
  • tipifarnib
  • SST-0001
  • veliparib
  • silmitasertib
  • afuresertib hydrochloride
  • CUDC-907
  • MV-NIS Vaccine
  • venetoclax
  • RG-7598
  • LGH-447
  • DCRM-1711
  • GSK-2857916

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7074IDB

Summary

Global Markets Direct's, 'Refractory Multiple Myeloma - Pipeline Review, H2 2015', provides an overview of the Refractory Multiple Myeloma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Refractory Multiple Myeloma Overview
  • Therapeutics Development
    • Pipeline Products for Refractory Multiple Myeloma - Overview
    • Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis
  • Refractory Multiple Myeloma - Therapeutics under Development by Companies
  • Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes
  • Refractory Multiple Myeloma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Refractory Multiple Myeloma - Products under Development by Companies
  • Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes
  • Refractory Multiple Myeloma - Companies Involved in Therapeutics Development
    • 4SC AG
    • AbbVie Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Altor BioScience Corporation
    • Arno Therapeutics, Inc.
    • Array BioPharma Inc.
    • Astellas Pharma Inc.
    • Astex Pharmaceuticals, Inc.
    • Biotest AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Calithera Biosciences, Inc.
    • Celgene Corporation
    • Cellectar Biosciences, Inc.
    • Cleave Biosciences
    • CureTech Ltd.
    • Curis, Inc.
    • Dicerna Pharmaceuticals, Inc.
    • Exelixis, Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Immunomedics, Inc.
    • Jasco Pharmaceuticals, LLC.
    • Johnson & Johnson
    • JW Pharmaceutical Corporation
    • Karyopharm Therapeutics, Inc.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Millennium Pharmaceuticals, Inc.
    • MorphoSys AG
    • Novartis AG
    • Oncolytics Biotech Inc.
    • Oncopeptides AB
    • Onyx Pharmaceuticals, Inc.
    • Otsuka Holdings Co., Ltd.
    • Patrys Limited
    • Pfizer Inc.
    • Pharma Mar, S.A.
    • Prolexys Pharmaceuticals, Inc.
    • Sanofi
    • Sigma-Tau S.p.A.
    • Stemline Therapeutics, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Synta Pharmaceuticals Corp.
    • Threshold Pharmaceuticals, Inc.
    • Vivolux AB
  • Refractory Multiple Myeloma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 4SC-202 - Drug Profile
    • ABBV-838 - Drug Profile
    • ACP-196 - Drug Profile
    • ACY-241 - Drug Profile
    • afuresertib hydrochloride - Drug Profile
    • alisertib - Drug Profile
    • alpelisib - Drug Profile
    • ALT-801 - Drug Profile
    • ALT-803 - Drug Profile
    • amrubicin hydrochloride - Drug Profile
    • AR-42 - Drug Profile
    • AT-7519 - Drug Profile
    • AT-9283 - Drug Profile
    • B-701 - Drug Profile
    • bendamustine hydrochloride - Drug Profile
    • BI-836909 - Drug Profile
    • BMS-986016 - Drug Profile
    • cabozantinib s-malate - Drug Profile
    • carfilzomib - Drug Profile
    • CB-5083 - Drug Profile
    • CB-839 - Drug Profile
    • CC-90002 - Drug Profile
    • Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile
    • CUDC-907 - Drug Profile
    • CWP-291 - Drug Profile
    • daratumumab - Drug Profile
    • DCRM-1711 - Drug Profile
    • DKN-01 - Drug Profile
    • elotuzumab - Drug Profile
    • erismodegib - Drug Profile
    • evofosfamide - Drug Profile
    • filanesib - Drug Profile
    • ganetespib - Drug Profile
    • GSK-2857916 - Drug Profile
    • I131-CLR1404 - Drug Profile
    • ibrutinib - Drug Profile
    • indatuximab ravtansine - Drug Profile
    • inebilizumab - Drug Profile
    • ipilimumab - Drug Profile
    • isatuximab - Drug Profile
    • ixazomib citrate - Drug Profile
    • JP-11646 - Drug Profile
    • LCL-161 - Drug Profile
    • linsitinib - Drug Profile
    • marizomib - Drug Profile
    • Melflufen - Drug Profile
    • milatuzumab - Drug Profile
    • MOR-202 - Drug Profile
    • MV-NIS - Drug Profile
    • NL-101 - Drug Profile
    • OPB-51602 - Drug Profile
    • oprozomib - Drug Profile
    • palbociclib - Drug Profile
    • PATSM-6 - Drug Profile
    • pelareorep - Drug Profile
    • pembrolizumab - Drug Profile
    • pidilizumab - Drug Profile
    • PIM-447 - Drug Profile
    • plerixafor - Drug Profile
    • plitidepsin - Drug Profile
    • PRLX-93936 - Drug Profile
    • Recombinant Protein for Oncology - Drug Profile
    • ricolinostat - Drug Profile
    • roneparstat - Drug Profile
    • RRX-001 - Drug Profile
    • sapanisertib - Drug Profile
    • selinexor - Drug Profile
    • SL-401 - Drug Profile
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
    • ulocuplumab - Drug Profile
    • urelumab - Drug Profile
    • vemurafenib - Drug Profile
    • venetoclax - Drug Profile
    • VLX-1570 - Drug Profile
    • vorinostat - Drug Profile
  • Refractory Multiple Myeloma - Recent Pipeline Updates
  • Refractory Multiple Myeloma - Dormant Projects
  • Refractory Multiple Myeloma - Discontinued Products
  • Refractory Multiple Myeloma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Refractory Multiple Myeloma, H2 2015
  • Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Refractory Multiple Myeloma - Pipeline by 4SC AG, H2 2015
  • Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Biotest AG, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Calithera Biosciences, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Cleave Biosciences, H2 2015
  • Refractory Multiple Myeloma - Pipeline by CureTech Ltd., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Curis, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Immunomedics, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H2 2015
  • Refractory Multiple Myeloma - Pipeline by JW Pharmaceutical Corporation, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by MedImmune, LLC, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Merck & Co., Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by MorphoSys AG, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Novartis AG, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Patrys Limited, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Sanofi, H2 2015
  • Refractory Multiple Myeloma - Pipeline by Sigma-Tau S.p.A., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
  • Refractory Multiple Myeloma - Pipeline by Vivolux AB, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H2 2015
  • Refractory Multiple Myeloma - Dormant Projects, H2 2015
  • Refractory Multiple Myeloma - Dormant Projects (Contd..1), H2 2015
  • Refractory Multiple Myeloma - Dormant Projects (Contd..2), H2 2015
  • Refractory Multiple Myeloma - Dormant Projects (Contd..3), H2 2015
  • Refractory Multiple Myeloma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Refractory Multiple Myeloma, H2 2015
  • Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top